Why is Marksans Pharma falling/rising?

As of 11-Nov, Marksans Pharma Ltd is experiencing a rise in its stock price, currently at Rs 194.40, reflecting an increase of Rs 7.35 or 3.93%. The stock has shown a positive performance today, outperforming its sector by 4.06%, and has gained 6.37% over the last two days. Despite touching an intraday high of Rs 196.5, the stock's trading volume indicates a decline in investor participation, with a 9.04% drop in delivery volume compared to the 5-day average. While the stock has performed well in the short term, with a 4.10% increase over the past week and a 7.08% increase over the past month, it has significantly underperformed on a year-to-date basis with a decline of 34.38%. The company maintains a high management efficiency with a return on equity (ROE) of 17.66% and a low debt-to-equity ratio, which may contribute positively to investor sentiment.
In the broader market context, the stock's recent performance contrasts with the benchmark Sensex, which has only increased by 0.49% over the past week and 1.66% over the past month. This suggests that Marksans Pharma's short-term gains are notable compared to the overall market. However, the company has faced challenges in the long term, including a decline in operating profit and negative results reported in June 2025. Despite high institutional holdings that may provide some stability, the stock has underperformed the market over the past year, generating a return of -32.72% compared to the Sensex's positive return of 5.50%. This mixed performance indicates that while there may be short-term optimism, underlying issues could continue to weigh on the stock's long-term prospects.